Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
08/10/2026 13:31
BRIEF-Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer Oct 8 (Reuters) - Vir Biotechnology, Inc. VIR.O:
VIR BIOTECHNOLOGY ANNOUNCES PSMA-TARGETED PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 RECEIVED FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF PROSTATE CANCER
VIR BIOTECHNOLOGY - PHASE 3 TRIALS FOR VIR-5500 ANTICIPATED TO BEGIN IN 2027
Source text: ID:nBw5WRRp7a
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO